Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ferrous Gluconate,Ascorbic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : XOMA
Deal Size : $22.0 million
Deal Type : Financing
Dar© Secures $22M Royalty Financing for Women's Health Product Candidates
Details : Proceeds will advance Ovaprene, an intravaginal contraceptive ring, and Sildenafil Cream, a potential FDA-approved treatment for female sexual arousal disorder.
Brand Name : Ovaprene
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 30, 2024
Lead Product(s) : Ferrous Gluconate,Ascorbic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : XOMA
Deal Size : $22.0 million
Deal Type : Financing
Lead Product(s) : Ascorbic Acid,Glutathione,Sodium Bicarbonate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renovion Reports Positive Results from Phase 2 CLIMB Study of ARINA-1
Details : ARINA-1 is a new nebulized product composed of ascorbic acid, glutathione, and bicarbonate, currently in phase 2 trials for treating patients with Non-cystic Fibrosis Bronchiectasis.
Brand Name : Arina-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 30, 2024
Lead Product(s) : Ascorbic Acid,Glutathione,Sodium Bicarbonate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ascorbic Acid,Glutathione,Bicarbonate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renovion Completes Enrollment of Adult Patients in Phase 2 CLIMB Study in Bronchiectasis
Details : ARINA-1 is a new nebulized product comprising ascorbic acid, glutathione, and bicarbonate, currently investigated in phase 2 trials for treating Non-cystic Fibrosis Bronchiectasis.
Brand Name : Arina-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 11, 2024
Lead Product(s) : Ascorbic Acid,Glutathione,Bicarbonate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Glutathione,Ascorbic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™
Details : DuraGraft is a first-in-class CE marked intra-operative graft storage solution used during bypass surgeries that is authorized for use in Europe and other countries outside of the United States.
Brand Name : DuraGraft
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 06, 2023
Lead Product(s) : Glutathione,Ascorbic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Echinacea,Zinc,Ascorbic Acid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : EZC Pak is the proven over-the-counter rapid immune support solution that contains professional strength doses of Echinacea, zinc, vitamin C (and sometimes vitamin D). It is being indicated for the reduction in illness duration for patients with upper re...
Brand Name : EZC Pak
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 03, 2023
Lead Product(s) : Echinacea,Zinc,Ascorbic Acid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ascorbic Acid,Glutathione
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Details : ARINA-1 (ascorbic acid) is an investigational nebulized therapy to prevent the progression of bronchiolitis obliterans syndrome (BOS) progression in individuals with a bilateral lung transplant.
Brand Name : ARINA-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 18, 2023
Lead Product(s) : Ascorbic Acid,Glutathione
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ascorbic Acid,Glutathione
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ARINA-1 (ascorbic acid), an investigational nebulized therapy, to treat adults with non-CF bronchiectasis,has been shown to have significant mucolytic activity, as well as robust anti-inflammatory properties.
Brand Name : ARINA-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 02, 2022
Lead Product(s) : Ascorbic Acid,Glutathione
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ferrous Gluconate,Ascorbic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Bayer AG
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ovaprene®, an investigational hormone-free monthly intravaginal contraceptive, prevented essentially all sperm from entering the cervical canal across all women and all cycles evaluated.
Brand Name : Ovaprene
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 10, 2022
Lead Product(s) : Ferrous Gluconate,Ascorbic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Bayer AG
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ascorbic Acid
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renovion Receives Notice of Study May Proceed Status for Lung Transplant Program
Details : ARINA-1 (ascorbic acid) is a first-in-class therapy that addresses deficiencies in the innate immune system that occur in chronic inflammatory airway diseases, such as non-CF bronchiectasis, COPD, and lung transplant.
Brand Name : ARINA-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 02, 2022
Lead Product(s) : Ascorbic Acid
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ascorbic Acid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renovion Provides Regulatory Update and Initiation of Clinical Program in Non-CF Bronchiectasis
Details : ARINA-1, novel nebulized therapy delivered to the lungs to treat pulmonary diseases, it clears mucus and reduces damaging inflammation in the airways to restore lung health in non-cystic fibrosis bronchiectasis.
Brand Name : ARINA-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 07, 2022
Lead Product(s) : Ascorbic Acid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?